The Next Opioid Crisis Is Legal and On the Shelf

On July 29, 2025 the FDA formally recommended that concentrated 7-hydroxymitragynine be classified as a Schedule I controlled substance. FDA Commissioner Marty Makary called 7-OH an opioid more potent than morphine and warned it could trigger another wave of the opioid epidemic.

That was nearly nine months ago. The DEA has not acted. No proposed rule. No notice of intent. Nothing in the Federal Register.

This is not new. In 2016 the DEA announced it would temporarily schedule kratom's active compounds. Over 140,000 public comments and a congressional letter killed the effort. The DEA withdrew. The FDA submitted a scheduling recommendation to HHS in 2017. In 2018 HHS quietly rescinded it, calling the FDA's evidence "disappointingly poor." That rescission was kept secret for three years. Now the FDA has come back with a narrower and better-supported case targeting concentrated 7-OH specifically. And the DEA is once again silent.

CDC poison center data: 258 kratom-related exposure reports in 2015. 3,434 in 2025. 233 associated deaths over the decade, 79% involving multiple substances. In Los Angeles County, a cluster of fatal overdoses was tied specifically to synthetic kratom compounds. The CDC linked the 2025 surge directly to the emergence of high-potency semisynthetic 7-OH products.

Every one of those numbers is an undercount. Standard clinical drug panels do not detect kratom alkaloids. If mass spectrometry was not specifically ordered, kratom involvement was missed.

Ohio permanently classified synthetic mitragynine-related compounds as Schedule I on April 13, 2026. Florida banned concentrated 7-OH products in August 2025. Oregon caps 7-OH at 2% of total alkaloid content. California's health department has determined kratom is not legal to sell as food or drug under existing state law. Six states ban kratom outright.

The federal government recommended Schedule I nine months ago. The states are building the architecture themselves because Washington has not.

The pharmacology is not complicated. Kratom leaf contains mitragynine, a partial opioid receptor agonist. At low doses it stimulates. At higher doses it sedates. The plant has been used traditionally in Southeast Asia for centuries.

7-hydroxymitragynine is a different compound. It is present in fresh kratom leaf at less than 0.01%. The products now on retail shelves are not delivering trace amounts. They are delivering milligram-range doses of a full mu-opioid receptor agonist directly. Tolerance. Dependence. Withdrawal. The full opioid profile.

Approximately 25% of regular US users in a convenience sample met criteria for Kratom Use Disorder. Tolerance was the most common symptom at 81%. Withdrawal at 68%. Johns Hopkins now recognizes KUD as a clinical entity.

Irritability during both active use and withdrawal is established in the clinical literature. Not speculative. Documented. A Phase 1 clinical trial found that mitragynine improved attention at low doses while simultaneously increasing errors on a validated measure of impulse control. Better focus with less braking.

Kratom irreversibly inhibits CYP3A4 and CYP2D6, the liver enzymes responsible for metabolizing approximately half of all prescription drugs. If your college-age kid is on sertraline or escitalopram and buying a kratom shot at the campus convenience store, their SSRI exposure is being elevated beyond the therapeutic window. The result can be serotonin syndrome: agitation, confusion, rapid heart rate, seizures. Kratom's own serotonergic activity compounds the risk.

This is not theoretical. It is the mechanism that explains why 79% of kratom-associated deaths involve multiple substances. Kratom blocks the body's ability to clear other drugs.

Babies are being born dependent on it. Peer-reviewed case reports document neonatal abstinence syndrome requiring morphine treatment in the NICU. One infant developed withdrawal at 33 hours of life. Prenatal drug screens do not detect kratom.

Standard drug tests will not find it. If you do not ask by name you will not know.

Feel Free Classic by Botanic Tonics has sold more than 129 million servings since 2020 across 15,000 retail locations. In May 2023 the FDA and U.S. Marshals seized more than 250,000 units from the company's Oklahoma facility. In October 2025 a federal court approved an $8.75 million class action settlement involving more than 40,000 plaintiffs who alleged the company failed to disclose the health risks and addictive potential of its product. The complaint documented free sample distribution at USC, Florida State and the University of Texas at Austin, targeting college students during finals week.

The company's own label says the product "can be habit-forming." No new dietary ingredient notification has been accepted by the FDA. The product is still on the shelf.

If you are a policy maker: the FDA has done its part. The states are moving. The question is whether your jurisdiction has a framework that distinguishes concentrated 7-OH from natural leaf, or whether you are leaving that to the retail market.

If you are a clinician: kratom will not show up on your standard panels. Ask about it by name. If your patient is on SSRIs, benzodiazepines or statins, kratom co-use creates pharmacokinetic interactions that will not appear on routine toxicology.

If you are a parent: this product is legal, marketed as a wellness drink and was handed out free on college campuses. Standard drug tests will not detect it. If your child is on any psychiatric medication the interaction risk is real. Ask about kratom by name. Ask about Feel Free. Ask about kava shots. The screens will not do it for you.

If you are an educator: this is the next chapter of the opioid crisis arriving through convenience stores and influencer campaigns. A significant percentage of your students are on SSRIs that interact dangerously with these products. Awareness campaigns that name kratom specifically are overdue.

I have published a comprehensive 30-page technical memo covering the full regulatory timeline, the pharmacological profile, drug interaction mechanisms, neonatal abstinence cases, the Feel Free product case study, dependence and withdrawal evidence, dosage thresholds and 77 peer-reviewed citations.

If this piece was useful, forward it. The person who needs to read it may not know this product exists yet.

Mark Haas is CEO of The Helmsman Group LLC, a Portland-based food science and regulatory consulting firm, and co-founder of RegulateCPG, an AI-powered regulatory compliance platform for the food and beverage industry. He is a member of the Association of Food and Drug Officials (AFDO) and holds a Process Authority credential recognized by the FDA, one of approximately 100 practitioners nationally. His regulatory expertise spans 21 CFR Parts 101, 111 and 190, the framework under which kratom products have been evaluated and determined to be unlawfully marketed. He has published peer-reviewed research in opioid receptor pharmacology at the University of Washington with Charles Chavkin, Ph.D., whose laboratory produced foundational work on kappa opioid receptor signaling now cited in the kratom pharmacology literature. He has formulated over 500 consumer brands representing more than $5 billion in retail value and writes on food safety, regulatory science and industry strategy for more than 50,000 subscribers.

For more insights on using regulatory compliance as competitive advantage, visit regulatecpg.com, Helmsmangroup.com or connect with Mark on LinkedIn.

Legal Disclaimer:
This article discusses regulatory strategy and compliance approaches but does not constitute legal advice. Companies should consult qualified food law attorneys and regulatory counsel for guidance on specific labeling decisions and regulatory interpretations applicable to their products.